Wall Street analysts expect Insulet Corporation (NASDAQ:PODD) to report $114.24 million in sales for the current quarter, Zacks reports. Nine analysts have provided estimates for Insulet Corporation’s earnings. The lowest sales estimate is $108.70 million and the highest is $117.44 million. Insulet Corporation reported sales of $94.87 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 20.4%. The firm is scheduled to issue its next quarterly earnings results on Thursday, November 2nd.

According to Zacks, analysts expect that Insulet Corporation will report full year sales of $114.24 million for the current financial year, with estimates ranging from $433.00 million to $454.09 million. For the next year, analysts anticipate that the business will post sales of $536.65 million per share, with estimates ranging from $504.90 million to $571.17 million. Zacks’ sales calculations are an average based on a survey of analysts that follow Insulet Corporation.

Insulet Corporation (NASDAQ:PODD) last released its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported ($0.13) EPS for the quarter, meeting analysts’ consensus estimates of ($0.13). Insulet Corporation had a negative return on equity of 46.74% and a negative net margin of 7.30%. The firm had revenue of $110 million for the quarter, compared to analyst estimates of $106.23 million. During the same quarter in the previous year, the company posted ($0.08) EPS. The business’s revenue was up 26.0% on a year-over-year basis.

A number of brokerages have recently issued reports on PODD. B. Riley reaffirmed a “neutral” rating and set a $44.00 price objective on shares of Insulet Corporation in a research note on Tuesday, May 9th. Oppenheimer Holdings, Inc. set a $55.00 price objective on Insulet Corporation and gave the company a “hold” rating in a research note on Friday, August 4th. Northland Securities reaffirmed a “buy” rating on shares of Insulet Corporation in a research note on Friday, August 4th. Jefferies Group LLC reaffirmed a “buy” rating and set a $58.00 price objective (up from $48.00) on shares of Insulet Corporation in a research note on Wednesday, August 9th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $63.00 price objective (up from $52.00) on shares of Insulet Corporation in a research note on Friday, August 4th. Eight research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $50.46.

Several hedge funds have recently bought and sold shares of the company. FMR LLC boosted its stake in Insulet Corporation by 0.5% in the second quarter. FMR LLC now owns 8,687,487 shares of the medical instruments supplier’s stock valued at $445,755,000 after buying an additional 39,836 shares during the last quarter. Capital Research Global Investors boosted its stake in Insulet Corporation by 2.5% in the second quarter. Capital Research Global Investors now owns 5,883,633 shares of the medical instruments supplier’s stock valued at $301,889,000 after buying an additional 145,724 shares during the last quarter. Vanguard Group Inc. boosted its stake in Insulet Corporation by 2.2% in the second quarter. Vanguard Group Inc. now owns 4,655,119 shares of the medical instruments supplier’s stock valued at $238,854,000 after buying an additional 98,272 shares during the last quarter. BlackRock Inc. boosted its stake in Insulet Corporation by 7,285.2% in the first quarter. BlackRock Inc. now owns 4,194,117 shares of the medical instruments supplier’s stock valued at $180,724,000 after buying an additional 4,137,326 shares during the last quarter. Finally, Clearbridge Investments LLC boosted its stake in Insulet Corporation by 64.2% in the first quarter. Clearbridge Investments LLC now owns 2,379,224 shares of the medical instruments supplier’s stock valued at $102,521,000 after buying an additional 930,062 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: This report was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/insulet-corporation-podd-expected-to-post-quarterly-sales-of-114-24-million/1492761.html.

Shares of Insulet Corporation (NASDAQ:PODD) opened at 54.26 on Wednesday. The firm has a 50 day moving average price of $51.50 and a 200-day moving average price of $45.38. The company’s market cap is $3.15 billion. Insulet Corporation has a 52-week low of $30.69 and a 52-week high of $55.46.

About Insulet Corporation

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Get a free copy of the Zacks research report on Insulet Corporation (PODD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insulet Corporation (NASDAQ:PODD)

Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.